| scholarly article | Q13442814 |
| P50 | author | Jeffrey Ravetch | Q1359564 |
| Falk Nimmerjahn | Q1394084 | ||
| P2093 | author name string | James C Paulson | |
| David J Ashline | |||
| Robert M Anthony | |||
| Vernon N Reinhold | |||
| P2860 | cites work | A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha 2-3)Gal- sequences of glycophorin A | Q24643787 |
| The antiinflammatory activity of IgG: the intravenous IgG paradox | Q24676548 | ||
| A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission | Q28286390 | ||
| Siglecs and their roles in the immune system | Q28294469 | ||
| Congruent strategies for carbohydrate sequencing. 1. Mining structural details by MSn | Q33224229 | ||
| Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor | Q33335777 | ||
| Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease | Q33347581 | ||
| Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells | Q33371273 | ||
| FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin | Q33373963 | ||
| From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins | Q33860728 | ||
| Sialic acid-specific lectins: occurrence, specificity and function | Q33994838 | ||
| Differential expression of five sialyltransferase genes in human tissues. | Q34329973 | ||
| Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins | Q34623034 | ||
| Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells | Q35023814 | ||
| Characterization of a Plasmodium falciparum erythrocyte-binding protein paralogous to EBA-175 | Q35869245 | ||
| Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors | Q36228422 | ||
| Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies | Q36370217 | ||
| Immune regulation by the ST6Gal sialyltransferase | Q36475650 | ||
| The impact of glycosylation on the biological function and structure of human immunoglobulins. | Q36618276 | ||
| Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides | Q36849871 | ||
| Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues | Q38298614 | ||
| Specificity of S fimbriae on recombinant Escherichia coli: preferential binding to gangliosides expressing NeuGc alpha (2-3)Gal and NeuAc alpha (2-8)NeuAc. | Q40267143 | ||
| Divergent immunoglobulin g subclass activity through selective Fc receptor binding | Q40344836 | ||
| Carbohydrate structural isomers analyzed by sequential mass spectrometry | Q41863702 | ||
| A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins | Q42162369 | ||
| The glycosylation of human serum IgD and IgE and the accessibility of identified oligomannose structures for interaction with mannan-binding lectin | Q45158584 | ||
| Large-scale expression of recombinant sialyltransferases and comparison of their kinetic properties with native enzymes | Q46155748 | ||
| In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase | Q46723270 | ||
| Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. | Q51118036 | ||
| Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation | Q57253538 | ||
| α2,3-Sialyltransferase-IV is essential for L-selectin ligand function in inflammation | Q57445739 | ||
| Ultrastructural localization of a macrophage-restricted sialic acid binding hemagglutinin, SER, in macrophage-hematopoietic cell clusters | Q68541245 | ||
| Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G | Q68983739 | ||
| Lectin analysis of human immunoglobulin G N-glycan sialylation | Q73334585 | ||
| P433 | issue | 5874 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| P304 | page(s) | 373-376 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. | |
| P478 | volume | 320 |
| Q42732008 | 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland |
| Q35838507 | A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
| Q33742283 | A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation |
| Q36008257 | A common glycan structure on immunoglobulin G for enhancement of effector functions |
| Q37756017 | A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. |
| Q26827579 | A perspective on the structure and receptor binding properties of immunoglobulin G Fc |
| Q30368704 | A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines. |
| Q64262117 | A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity |
| Q35289292 | A single glycan on IgE is indispensable for initiation of anaphylaxis. |
| Q90461272 | Abberant Immunoglobulin G Glycosylation in Rheumatoid Arthritis by LTQ-ESI-MS |
| Q36950893 | Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients |
| Q57583344 | Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target |
| Q37986822 | Acute phase glycoproteins: bystanders or participants in carcinogenesis? |
| Q37676032 | Advances in diagnosing and managing antibody-mediated rejection |
| Q83335115 | Advances in the assessment and control of the effector functions of therapeutic antibodies |
| Q37237410 | Advances in the understanding of the mechanism of action of IVIg |
| Q37068434 | Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors |
| Q94465707 | An Engineered Pathway for Production of Terminally Sialylated N-glycoproteins in the Periplasm of Escherichia coli |
| Q51428039 | An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report. |
| Q24600487 | An open-label dosing study to evaluate the safety and effects of a dietary plant-derived polysaccharide supplement on the N-glycosylation status of serum glycoproteins in healthy subjects |
| Q28728886 | Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation |
| Q49129602 | Analysis of gamma-globulin mobility on routine clinical CE equipment: exploring its molecular basis and potential clinical utility |
| Q33903461 | Analytical and Functional Aspects of Antibody Sialylation. |
| Q36125875 | Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy |
| Q35590968 | Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment |
| Q34199547 | Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene |
| Q36255087 | Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis |
| Q84549496 | Anti-inflammatory activity of sublingual immunoglobulin (SLIG) in a murine model of allergen-driven airway inflammation |
| Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
| Q50540781 | Antibody-mediated sialidase activity in blood serum of patients with multiple myeloma. |
| Q30616406 | Antibody-mediated trapping of helminth larvae requires CD11b and Fcγ receptor I. |
| Q35959717 | Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination |
| Q27687250 | Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases |
| Q36239724 | Arthrobacter endo-beta-N-acetylglucosaminidase shows transglycosylation activity on complex-type N-glycan oxazolines: one-pot conversion of ribonuclease B to sialylated ribonuclease C. |
| Q36225198 | Association of systemic lupus erythematosus with decreased immunosuppressive potential of the IgG glycome |
| Q36517187 | At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody |
| Q41762205 | Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies |
| Q39067021 | Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis |
| Q33403107 | B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo |
| Q26771404 | B cells with regulatory properties in transplantation tolerance |
| Q37065114 | B-cell-independent sialylation of IgG. |
| Q38936714 | Biological roles of glycans |
| Q38068530 | Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future |
| Q42583191 | Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. |
| Q57253418 | Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo |
| Q39276137 | CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies |
| Q38852467 | Can glycoprofiling be helpful in detecting prostate cancer? |
| Q35654967 | Carboxybetaine Modified Interface for Electrochemical Glycoprofiling of Antibodies Isolated from Human Serum. |
| Q37404476 | Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside |
| Q64118472 | Cardio-Immunology of Myocarditis: Focus on Immune Mechanisms and Treatment Options |
| Q26773052 | Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs |
| Q34772586 | Change in IgG1 Fc N-linked glycosylation in human lung cancer: age- and sex-related diagnostic potential |
| Q37629724 | Changes in IgG and total plasma protein glycomes in acute systemic inflammation |
| Q35878770 | Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination |
| Q37581781 | Chemical and chemoenzymatic synthesis of glycoproteins for deciphering functions |
| Q38081023 | Chemical assembly of N-glycoproteins: a refined toolbox to address a ubiquitous posttranslational modification |
| Q36852736 | Chemoenzymatic Glyco-engineering of Monoclonal Antibodies |
| Q36189447 | Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. |
| Q35555990 | Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor |
| Q37468164 | Chemoenzymatic synthesis and lectin array characterization of a class of N-glycan clusters. |
| Q47874093 | Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody-drug conjugates. |
| Q35820079 | Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression |
| Q92452874 | Choice of Host Cell Line Is Essential for the Functional Glycosylation of the Fc Region of Human IgG1 Inhibitors of Influenza B Viruses |
| Q36622214 | Chronic schistosome infection leads to modulation of granuloma formation and systemic immune suppression. |
| Q59801646 | Cis interaction between sialylated FcγRIIA and the αI-domain of Mac-1 limits antibody-mediated neutrophil recruitment |
| Q38309192 | Consequences of glycan truncation on Fc structural integrity |
| Q33420853 | Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity |
| Q44852748 | Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development |
| Q38045203 | Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy |
| Q35266458 | Cytoplasmic N-glycosyltransferase of Actinobacillus pleuropneumoniae is an inverting enzyme and recognizes the NX(S/T) consensus sequence |
| Q43168712 | DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells |
| Q38478867 | Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye. |
| Q39709073 | Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines |
| Q47804590 | Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity? |
| Q90723253 | Disruption of hepatocyte Sialylation drives a T cell-dependent pro-inflammatory immune tone |
| Q35939622 | Distinguishing N-acetylneuraminic acid linkage isomers on glycopeptides by ion mobility-mass spectrometry. |
| Q53313488 | Diversification of IgG effector functions. |
| Q41819438 | Dose-dependent inhibition of demyelination and microglia activation by IVIG. |
| Q36484438 | Efficacy of Intravenous Immunoglobulin in Neurological Diseases. |
| Q38847934 | Electrochemical lectin based biosensors as a label-free tool in glycomics. |
| Q26822552 | Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics |
| Q51321746 | Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. |
| Q35194874 | Emerging antibody products and Nicotiana manufacturing |
| Q64903536 | Emerging glycobiology tools: A renaissance in accessibility. |
| Q90496015 | Emerging immunotherapies for autoimmune kidney disease |
| Q37417435 | Emerging methods for the production of homogeneous human glycoproteins |
| Q35685635 | Emerging technologies for making glycan-defined glycoproteins |
| Q47220975 | Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease |
| Q33661333 | Engineering host cell lines to reduce terminal sialylation of secreted antibodies |
| Q37730868 | Engineering mammalian cells in bioprocessing - current achievements and future perspectives |
| Q38912355 | Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors. |
| Q35731540 | Enhanced Bacterial α(2,6)-Sialyltransferase Reaction through an Inhibition of Its Inherent Sialidase Activity by Dephosphorylation of Cytidine-5'-Monophosphate. |
| Q89992520 | Enhancement of sialylation in rIgG in glyco-engineered Chinese hamster ovary cells |
| Q33396115 | Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia |
| Q42132914 | Evaluation of a glycoengineered monoclonal antibody via LC-MS analysis in combination with multiple enzymatic digestion |
| Q30418119 | Evolutional and clinical implications of the epigenetic regulation of protein glycosylation. |
| Q51002069 | Expression and function of the inhibitory Fcγ-receptor in CIDP. |
| Q33416633 | Expression of IL4 (VNTR intron 3) and IL10 (-627) genes polymorphisms in childhood immune thrombocytopenic purpura |
| Q64079585 | Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine |
| Q28076303 | Fc gamma receptors: glycobiology and therapeutic prospects |
| Q38206710 | Fc glycan-modulated immunoglobulin G effector functions. |
| Q26799266 | Fc glycans of therapeutic antibodies as critical quality attributes |
| Q34994340 | Fc-glycosylation of IgG1 is modulated by B-cell stimuli |
| Q39217862 | Fcγ Receptor Heterogeneity in Leukocyte Functional Responses. |
| Q38615357 | Fcγ receptor pathways during active and passive immunization |
| Q37327690 | Fractionation of Fab glycosylated immunoglobulin G with concanavalin A chromatography unveils new structural properties of the molecule |
| Q52597179 | Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. |
| Q33402880 | Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice |
| Q26776225 | Future perspectives in target-specific immunotherapies of myasthenia gravis |
| Q88500050 | GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out |
| Q36932153 | General mechanism for modulating immunoglobulin effector function |
| Q52688333 | Generation of efficient mutants of endoglycosidase from Streptococcus pyogenes and their application in a novel one-pot transglycosylation reaction for antibody modification. |
| Q36179265 | Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. |
| Q34292392 | Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells |
| Q38034471 | Glyco-engineering in plants to produce human-like N-glycan structures |
| Q38028654 | GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins |
| Q37066000 | Glycoengineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation |
| Q36624721 | Glycosylation Profile of IgG in Moderate Kidney Dysfunction |
| Q38366332 | Glycosylation alterations in lung and brain cancer |
| Q37402407 | Glycosylation as a strategy to improve antibody-based therapeutics |
| Q39361301 | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. |
| Q35311994 | Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss |
| Q38807919 | Glycosylation of monoclonal antibody products: Current status and future prospects |
| Q33431066 | Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia |
| Q41941555 | Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling |
| Q27027997 | Glycotherapy: new advances inspire a reemergence of glycans in medicine |
| Q90455147 | Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System |
| Q38061236 | Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options |
| Q33936469 | High Performance IT-MS Sequencing of Glycans (Spatial Resolution of Ovalbumin Isomers). |
| Q35497686 | High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations |
| Q93062532 | High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease |
| Q98224836 | High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects |
| Q37532013 | High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases |
| Q47567099 | High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases |
| Q38797703 | High-throughput analysis of immunoglobulin G glycosylation |
| Q50496881 | Highly Efficient Synthesis of Multiantennary Bisected N-glycans Based on Imidates. |
| Q49932309 | Hochdosierte intravenöse Immunglobuline bei dermatologischen Autoimmunerkrankungen |
| Q92605184 | Homogeneous production and characterization of recombinant N-GlcNAc-protein in Pichia pastoris |
| Q91776771 | Human DC-SIGN and CD23 do not interact with human IgG |
| Q39218564 | Human intravenous immunoglobulin (hIVIG) inhibits anti-CD32 antibody binding to canine DH82 cells and canine monocytes in vitro |
| Q36963945 | Human plasma protein N-glycosylation |
| Q38699812 | IVIG-mediated effector functions in autoimmune and inflammatory diseases |
| Q27497796 | IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Aβ pathology |
| Q33399346 | IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. |
| Q37018736 | Identification of a receptor required for the anti-inflammatory activity of IVIG. |
| Q46978895 | Identification of manipulated variables for a glycosylation control strategy |
| Q36946538 | Identification of novel plasma glycosylation-associated markers of aging |
| Q92491366 | IgA subclasses have different effector functions associated with distinct glycosylation profiles |
| Q92027568 | IgE Glycosylation in Health and Disease |
| Q88445153 | IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acids |
| Q33438726 | IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity |
| Q40108236 | IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice. |
| Q34368678 | IgG subclasses and allotypes: from structure to effector functions |
| Q28069362 | Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies |
| Q86421496 | Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin |
| Q58861272 | Immunoglobulines intraveineuses dans les maladies auto-immunes et inflammatoires : au-delà d’une simple substitution |
| Q39107736 | Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection |
| Q33393823 | Immunomodulatory drugs and their application to the management of canine immune-mediated disease |
| Q43297973 | Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice |
| Q90681706 | Immunotherapy in myasthenia gravis in the era of biologics |
| Q92613729 | Impact of Fc N-glycan sialylation on IgG structure |
| Q37140095 | Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy |
| Q37342888 | Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma |
| Q59132146 | Improving Immunotherapy Through Glycodesign |
| Q40602343 | In planta protein sialylation through overexpression of the respective mammalian pathway |
| Q38039963 | In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity |
| Q41880662 | In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap |
| Q58861264 | Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques |
| Q26781290 | Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity |
| Q27010099 | Infection, inflammation and host carbohydrates: a Glyco-Evasion Hypothesis |
| Q89985874 | Inflammatory dilated cardiomyopathy : Etiology and clinical management |
| Q64925019 | Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. |
| Q64253803 | Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus |
| Q51081577 | Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO. |
| Q34999126 | Intramolecular N-glycan/polypeptide interactions observed at multiple N-glycan remodeling steps through [(13)C,(15)N]-N-acetylglucosamine labeling of immunoglobulin G1. |
| Q36959840 | Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. |
| Q27000371 | Intravenous immunoglobulin and Alzheimer's disease: what now? |
| Q38308436 | Intravenous immunoglobulin in neurology--mode of action and clinical efficacy |
| Q36302368 | Intravenous immunoglobulin in the management of lupus nephritis. |
| Q38495457 | Intravenous immunoglobulin in the treatment of neurologic disorders |
| Q37873722 | Intravenous immunoglobulin therapy in rheumatic diseases |
| Q33405903 | Intravenous immunoglobulin therapy: how does IgG modulate the immune system? |
| Q37732919 | Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients |
| Q38133405 | Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute |
| Q38304255 | Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future |
| Q37626118 | Intravenous immunoglobulins--understanding properties and mechanisms |
| Q39933128 | Intravenous immunoglobulins. Current understanding and future directions. |
| Q37774870 | Involvement of aberrant glycosylation in thyroid cancer |
| Q27671018 | Lanthanide binding and IgG affinity construct: Potential applications in solution NMR, MRI, and luminescence microscopy |
| Q51065097 | Letter to the editor. Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor. |
| Q36566645 | Live-Cell Labeling of Specific Protein Glycoforms by Proximity-Enhanced Bioorthogonal Ligation |
| Q34803358 | Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn |
| Q37578785 | Low-affinity Fcgamma receptors, autoimmunity and infection |
| Q37290930 | Mammalian glycosylation in immunity |
| Q35108694 | Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes |
| Q35097817 | Mass spectrometry and glycomics |
| Q37274089 | Mass spectrometry and the emerging field of glycomics |
| Q34247694 | Mass spectrometry in the analysis of N-linked and O-linked glycans |
| Q42375731 | Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action? |
| Q37737994 | Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. |
| Q33389428 | Mechanisms of action of intravenous immunoglobulins |
| Q38452524 | Metabolic glycoengineering bacteria for therapeutic, recombinant protein, and metabolite production applications |
| Q42917883 | Metabolic labeling of glycoconjugates with photocrosslinking sugars |
| Q41940868 | Mgat2 ablation in the myeloid lineage leads to defective glycoantigen T cell responses |
| Q93052135 | Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo |
| Q42544138 | Mixed Zwitterion-Based Self-Assembled Monolayer Interface for Impedimetric Glycomic Analyses of Human IgG Samples in an Array Format |
| Q41677985 | Modulating IgG effector function by Fc glycan engineering. |
| Q37860624 | Modulation of antibody effector function |
| Q39062945 | Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy |
| Q59047780 | Molecular and Cellular Pathways of Immunoglobulin G Activity In Vivo |
| Q42120158 | Molecular-scale features that govern the effects of O-glycosylation on a carbohydrate-binding module |
| Q27314948 | Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms |
| Q37461186 | Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. |
| Q28390264 | Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants |
| Q37484223 | Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG |
| Q37883497 | Myasthenia gravis in dogs with an emphasis on treatment and critical care management |
| Q41825788 | NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic |
| Q36249961 | NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation |
| Q35170050 | Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model |
| Q37091310 | Neuroprotection in stroke by complement inhibition and immunoglobulin therapy |
| Q92133744 | Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q33900595 | New paradigms for functional HIV-specific nonneutralizing antibodies |
| Q33383894 | New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura |
| Q52608527 | Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases. |
| Q34307304 | Novel data analysis tool for semiquantitative LC-MS-MS2 profiling of N-glycans |
| Q37979848 | Novel roles for the IgG Fc glycan |
| Q48987144 | One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates |
| Q52547591 | One-pot enzymatic glycan remodeling of a therapeutic monoclonal antibody by endoglycosidase S (Endo-S) from Streptococcus pyogenes. |
| Q33926907 | Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis |
| Q58555787 | Pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies |
| Q42387014 | Piperidine-based glycodendrons as protein N-glycan prosthetics |
| Q33409032 | Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia. |
| Q38246996 | Post-translational structural modifications of immunoglobulin G and their effect on biological activity |
| Q59330589 | Predicting the HILIC Retention Behavior of the N-Linked Glycopeptides Produced by Trypsin Digestion of Immunoglobulin Gs (IgGs) |
| Q47132349 | Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins |
| Q35873009 | Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid |
| Q36213335 | Production of α2,6-sialylated IgG1 in CHO cells |
| Q38408253 | Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis |
| Q43125937 | Profile of Jeffrey Ravetch. Interview by Philip Downey |
| Q36592223 | Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation. |
| Q35590264 | Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs |
| Q98466487 | Protein Glycoengineering: An Approach for Improving Protein Properties |
| Q58861270 | Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations |
| Q37999739 | Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach |
| Q41514933 | Rapid Glycopeptide Enrichment Using Cellulose Hydrophilic Interaction/Reversed-Phase StageTips |
| Q26752274 | Recent Advances in Clinical Glycoproteomics of Immunoglobulins (Igs) |
| Q50080563 | Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica |
| Q35899107 | Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. |
| Q42840500 | Recombinant proteins produced into yolk of genetically manipulated chickens are partly sialylated in N-glycan. |
| Q38957490 | Regulation of antibody effector functions through IgG Fc N-glycosylation |
| Q39251627 | Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease |
| Q37877263 | Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation |
| Q37622670 | Remodeling of marrow hematopoietic stem and progenitor cells by non-self ST6Gal-1 sialyltransferase |
| Q46364522 | Reply to Bayry et al.: The anti-inflammatory activity of sialylated IgG Fcs. |
| Q34315442 | Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding |
| Q38258905 | Review: intravenous immunoglobulin and B cells: when the product regulates the producer |
| Q36678337 | SIGN-R1, a C-type lectin, enhances apoptotic cell clearance through the complement deposition pathway by interacting with C1q in the spleen |
| Q38283308 | Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? |
| Q36164367 | Sialic Acid Derivatization for the Rapid Subclass- and Sialic Acid Linkage-Specific MALDI-TOF-MS Analysis of IgG Fc-Glycopeptides. |
| Q37586575 | Sialic acid level reflects the disturbances of glycosylation and acute-phase reaction in rheumatic diseases |
| Q33807752 | Sialic acid linkage differentiation of glycopeptides using capillary electrophoresis - electrospray ionization - mass spectrometry |
| Q36625410 | Sialic acids and autoimmune disease |
| Q43789293 | Sialidase inhibitors attenuate pulmonary fibrosis in a mouse model |
| Q55347406 | Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis. |
| Q48210931 | Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy |
| Q42316355 | Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury |
| Q36768842 | Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. |
| Q36352180 | Sialylation determines the nephritogenicity of IgG3 cryoglobulins |
| Q58004245 | Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's) |
| Q36266469 | Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity |
| Q57253368 | Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells |
| Q96136750 | Sialylation of immunoglobulin E is a determinant of allergic pathogenicity |
| Q33399238 | Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. |
| Q35959088 | Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study |
| Q58612152 | Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody |
| Q37117619 | Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag |
| Q53081892 | Site-specific immobilization of endoglycosidases for streamlined chemoenzymatic glycan remodeling of antibodies. |
| Q47286747 | Solid-Phase Enzymatic Remodeling Produces High Yields of Single Glycoform Antibodies |
| Q38066111 | Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives |
| Q27684721 | Structural Characterization of Anti-Inflammatory Immunoglobulin G Fc Proteins |
| Q38615376 | Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. |
| Q36624176 | Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa |
| Q38257861 | Structural documentation of glycan epitopes: sequential mass spectrometry and spectral matching |
| Q42364603 | Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health |
| Q50193260 | Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation |
| Q38239288 | Sweet and sour: the role of glycosylation for the anti-inflammatory activity of immunoglobulin G. |
| Q38851112 | Sweet but dangerous - the role of immunoglobulin G glycosylation in autoimmunity and inflammation. |
| Q33414406 | Sweetened antibodies against humoral autoimmunity: sialylated antibodies are required for IVIg-mediated therapy |
| Q37123859 | T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. |
| Q52338988 | TAILS N-Terminomics and proteomics reveal complex regulation of proteolytic cleavage by O-glycosylation. |
| Q38207937 | Targeting B cells and autoantibodies in the therapy of autoimmune diseases |
| Q52370705 | Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. |
| Q39531026 | Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease |
| Q37206320 | The Association Between Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional Study |
| Q88669457 | The Glycoscience of Immunity |
| Q90460486 | The Impact of Immunoglobulin G1 Fc Sialylation on Backbone Amide H/D Exchange |
| Q59360845 | The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine |
| Q39088502 | The Role and Function of Fcγ Receptors on Myeloid Cells |
| Q35116966 | The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III |
| Q47576940 | The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza |
| Q38066414 | The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade |
| Q38117686 | The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies |
| Q37638949 | The challenge and promise of glycomics |
| Q36213158 | The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q35014233 | The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis |
| Q90027632 | The history of IgG glycosylation and where we are now |
| Q101166851 | The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges |
| Q42116482 | The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc γ receptor |
| Q36670313 | The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody |
| Q37664865 | The other side of immunoglobulin G: suppressor of inflammation |
| Q36906422 | The regulatory power of glycans and their binding partners in immunity |
| Q37995919 | The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. |
| Q24321677 | The structure of human α-2,6-sialyltransferase reveals the binding mode of complex glycans |
| Q47410418 | The sweet spot for biologics: recent advances in characterization of biotherapeutic glycoproteins. |
| Q54217589 | Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. |
| Q39729881 | Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. |
| Q37807782 | Therapeutic use of immunoglobulins |
| Q34792884 | To B or not to B: B cells and the Th2-type immune response to helminths |
| Q47785877 | Tool for Rapid Analysis of Glycopeptide by Permethylation via One-Pot Site Mapping and Glycan Analysis. |
| Q42687289 | Total synthesis of the 2,6-sialylated immunoglobulin G glycopeptide fragment in homogeneous form. |
| Q36742409 | Toward a platform for comprehensive glycan sequencing |
| Q35123102 | Towards controlling the glycoform: a model framework linking extracellular metabolites to antibody glycosylation |
| Q26991899 | Translating basic mechanisms of IgG effector activity into next generation cancer therapies |
| Q37557375 | Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations. |
| Q53816522 | Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? |
| Q26822442 | Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives |
| Q56924750 | Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins |
| Q35063963 | Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G |
| Q57640701 | Treatment with Low Doses of Polyclonal Immunoglobulin Improves B Cell Function During Immune Reconstitution in a Murine Model |
| Q37456938 | Tregitope peptides: the active pharmaceutical ingredient of IVIG? |
| Q26853072 | Tregitope update: mechanism of action parallels IVIg |
| Q38125248 | Trichinella spiralis immunomodulation: an interactive multifactorial process |
| Q51361920 | Two N-terminally truncated variants of human β-galactoside α2,6 sialyltransferase I with distinct properties for in vitro protein glycosylation. |
| Q38232105 | Type I and type II Fc receptors regulate innate and adaptive immunity |
| Q42571075 | Ultrasensitive impedimetric lectin biosensors with efficient antifouling properties applied in glycoprofiling of human serum samples |
| Q89901292 | Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases |
| Q36253487 | Unusual transglycosylation activity of Flavobacterium meningosepticum endoglycosidases enables convergent chemoenzymatic synthesis of core fucosylated complex N-glycopeptides |
| Q45910300 | Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc- mouse model. |
| Q91694478 | Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer |
| Q39067348 | Will sialylation change intravenous immunoglobulin therapy in the future? |
| Q38055447 | With or without sugar? (A)glycosylation of therapeutic antibodies |
| Q85397964 | [Glycosylation-dependent effector function of IgG antibodies] |
| Q45964401 | [Optimizing therapy in patients with severe autoimmune blistering skin diseases]. |
| Q38615353 | bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression. |
Search more.